Avet, Charlotte
Sturino, Claudio
Grastilleur, Sébastien
Gouill, Christian Le http://orcid.org/0000-0002-6455-1800
Semache, Meriem
Gross, Florence
Gendron, Louis http://orcid.org/0000-0002-2058-8863
Bennani, Youssef
Mancini, Joseph A.
Sayegh, Camil E.
Bouvier, Michel http://orcid.org/0000-0003-1128-0100
Funding for this research was provided by:
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (IPCR 136753, MOP-123399)
Article History
Received: 5 June 2020
Accepted: 29 October 2020
First Online: 27 November 2020
Competing interests
: M.S. and F.G. were employees of IRIC at the Université de Montréal during their involvement in this work and are now employees of Domain Therapeutics N.A. to which some of the biosensors used in the present study were licensed for commercial purposes. C.S., Y.B., and C.E.S. were employees of Vertex Pharmaceuticals (Canada) during their involvement in this work and are now employees of Paraza Pharma, Inc., AdMare BioInnovations, and Ra Pharmaceuticals, respectively. Y.B. is CSO at AdMare BioInnovations and the Chair of the BOD of Domain Therapeutics. J.A.M. holds stocks of Vertex Pharmaceuticals. C.E.S. holds stocks of UCB. M.B. is the president of Domain Therapeutics SAB. C.S. and C.E.S. are among the inventers who filed a patent application related to the compound I-287. C.L.G. and M.B. are among the inventers who filed patent applications related to the biosensors used in this work. These biosensors were licensed to Domain Therapeutics for commercial use. C.A., S.G., and L.G. have no competing interests to declare.